Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus T2DM who are already being treated with insulin and other glucose-lowering medications. This Phase III study focuses on adults with T2DM who have had the condition for at least 90 days and meet certain health criteria. Participants will be randomly assigned to one of three groups elecoglipron at dose level 1, elecoglipron at dose level 2, or placebo. All treatments are taken orally once daily. The study treatment period lasts up to 40 weeks, during which participants continue their background insulin and glucose-lowering medications. During the study, participants will have regular assessments to monitor changes in blood sugar control, including Hemoglobin A1c HbA1c, body weight, blood pressure, and insulin dose. Researchers will also track safety, side effects, and tolerability. The main outcome is the change in HbA1c from baseline to Week 40. Overall, participation involves visits for monitoring and evaluations over approximately 40 weeks.
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.
Actively Recruiting
The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.
Actively Recruiting
Researchers are identifying and characterizing patients with Type 2 Diabetes Mellitus T2DM to support participation in current or future clinical studies focused on this condition. The study aims to observe trends in key medications used alongside diabetes treatments across various geographical areas, helping to better understand patient profiles and treatment patterns. Participants with T2DM who are inadequately managed by lifestyle changes alone or stable on glucose-lowering medications for at least 45 days will be observed. The study involves a single visit where assessments include collecting about 2 mL of blood and recording medical history, medication use, and HbA1c levels. This observational study does not administer treatments but gathers important health information. During the study visit, participants will provide demographic details, medical and surgical history, current medications, and blood samples to measure HbA1c levels. Researchers will also note referrals to ongoing or future T2DM studies. Participation requires signed consent and willingness to follow study procedures. The study concludes after the single visit, with no further follow-up required.
Actively Recruiting
Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.
Actively Recruiting
Healthy Volunteer
Metabolic dysfunction-associated steatotic liver disease MASLD, previously called non-alcoholic fatty liver disease NAFLD, is a common chronic liver condition linked to obesity, diabetes, and dyslipidemia. This condition ranges from simple fat buildup in the liver to more severe forms like metabolic dysfunction-associated steatohepatitis MASH, which can cause liver injury, advanced fibrosis, cirrhosis, or liver cancer. Patients with MASH also face risks of cardiovascular disease and death. Currently, there is no universally approved medication for MASH, and weight loss remains the main treatment approach. This study is a randomized controlled trial comparing two treatments for adults with obesity and biopsy-confirmed MASH and liver fibrosis. Participants will be randomly assigned to receive either metabolic surgery including Roux-en-Y Gastric Bypass or Sleeve Gastrectomy or medical treatment using incretin-based therapies such as liraglutide, semaglutide, or tirzepatide. The study will follow participants for two years, after which a repeat liver biopsy will assess changes in liver fibrosis and MASH. Participants will undergo a baseline liver biopsy if none is available, followed by treatment with either surgery or medication. Throughout the two-year study, they will be monitored regularly, with assessments including liver biopsies to measure fibrosis improvement or progression, resolution of MASH, weight changes, and quality of life. Safety and treatment adherence will also be tracked to understand the impact of these interventions on liver health and overall well-being.
Actively Recruiting
Researchers are investigating the safety and effectiveness of the Flexagon SFM system combined with the OTOLoc device for creating Ileo-colic and Colo-colonic anastomoses in patients undergoing colon surgery. This prospective, multi-center, single-arm clinical study focuses on patients requiring specific colon surgeries, such as Right Hemicolectomy or SigmoidLow Anterior resection, to better understand how these devices perform in surgical settings. The study involves delivering the Flexagon Self Forming Magnets SFMs and OTOLoc devices laparoscopically andor endoscopically into sections of the ileum or colon meant to be joined. OTOLoc devices help position and allow communication between two lumens until the anastomosis is fully formed by coupling SFMs. This procedure is evaluated for patients undergoing colon surgery, with the primary focus on successful anastomosis creation without needing reoperation within 30 days. Participants will be monitored for surgical outcomes, including the success of the anastomosis formation. Assessments will include medical clearance for surgery, post-surgical follow-up, and adherence to study requirements such as refraining from smoking. The trial tracks participants for at least 30 days after surgery to evaluate the primary outcome and ensure safety. Participation involves regular clinical visits and evaluations throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Flexagon Self Forming Magnet SFM system combined with OTOLoc for creating a gastro-jejunal anastomosis in patients undergoing gastric surgery. This prospective, multi-center, single-arm clinical study focuses on patients who require gastric surgery and aims to assess clinical outcomes using this device combination. Participants undergo gastric-jejunal anastomosis where the Flexagon SFM and OTOLoc devices are placed laparoscopically or endoscopically into targeted sections of the stomach and jejunum. The OTOLoc device is first deployed into the stomach wall to allow placement of the Flexagon SFM, which is then similarly positioned in the jejunum. These magnets are coupled to form the anastomosis, allowing fluid communication until it is fully established. During the study, participants will be monitored for the success of the anastomosis creation without needing reoperation within 30 days. The study includes clinical evaluations and medical clearances before surgery, with follow-up assessments to observe outcomes and safety. Participants must remain within a certain distance from the study center and adhere to study requirements such as refraining from smoking during follow-up, with total participation lasting through the postoperative period.
1-10 of 12
1